Literature DB >> 6622096

Deficient fumarylacetoacetate fumarylhydrolase activity in lymphocytes and fibroblasts from patients with hereditary tyrosinemia.

E A Kvittingen, S Halvorsen, E Jellum.   

Abstract

Fumarylacetoacetate fumarylhydrolase (E.C.3.7.1.2.), a liver enzyme involved in tyrosine degradation, is shown to be present in many human tissues and cells including lymphocytes, fibroblasts, and cultured amniotic fluid cells. The enzyme activity in lymphocytes from six patients with hereditary tyrosinemia (hepatorenal type) and fibroblasts from three patients, was found to be less than 10% of the activity in control subjects. In lymphocytes and fibroblasts from the parents (n = 16) of the patients the enzyme values were compatible with a heterozygote genotype. The lymphocyte enzyme pattern of the control subjects (n = 97), is complicated, and indicates possible enzyme variants.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6622096     DOI: 10.1203/00006450-198307000-00005

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  14 in total

1.  Type I hereditary tyrosinaemia: presentation of 11 cases.

Authors:  T Coşkun; I Ozalp; N Koçak; A Yüce; M Caglar; R Berger
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

2.  Liver transplantation in a 23-year-old tyrosinaemia patient: effects on the renal tubular dysfunction.

Authors:  E A Kvittingen; E Jellum; O Stokke; A Flatmark; A Bergan; G Sødal; S Halvorsen; E Schrumpf; E Gjone
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

3.  Prenatal diagnosis of hereditary tyrosinaemia type I by determination of fumarylacetoacetase in chorionic villus material.

Authors:  E A Kvittingen; P P Guibaud; P Divry; G Mandon; M O Rolland; Y Domenichini; C Jakobs; E Christensen
Journal:  Eur J Pediatr       Date:  1986-04       Impact factor: 3.183

4.  Hepatocellular carcinoma despite long-term survival in chronic tyrosinaemia I.

Authors:  S Z Kim; K G Kupke; L Ierardi-Curto; E Holme; J Greter; R M Tanguay; J Poudrier; M D'Astous; F Lettre; S H Hahn; H L Levy
Journal:  J Inherit Metab Dis       Date:  2000-12       Impact factor: 4.982

Review 5.  Current strategies for the treatment of hereditary tyrosinemia type I.

Authors:  Merja Ashorn; Sari Pitkänen; Matti K Salo; Markku Heikinheimo
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

6.  Hereditary tyrosinaemia type I: a long-term study of the relationship between the urinary excretions of succinylacetone and delta-aminolevulinic acid.

Authors:  H Schierbeek; G J Beukeveld; H van Faassen; F J van Spronsen; K Bijsterveld; E E Venekamp-Hoolsema; B G Wolthers; G P Smit
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

7.  Tyrosinemia type I--diagnostic issues and prenatal diagnosis.

Authors:  Sunita Bijarnia; Ratna D Puri; Jean Ruel; George F Gray; Linda Jenkinson; Ishwar C Verma
Journal:  Indian J Pediatr       Date:  2006-02       Impact factor: 1.967

8.  Renal failure in adult patients with hereditary tyrosinaemia type I.

Authors:  E A Kvittingen; T Talseth; S Halvorsen; C Jakobs; T Hovig; A Flatmark
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

9.  Hereditary tyrosinemia type I: strong association with haplotype 6 in French Canadians permits simple carrier detection and prenatal diagnosis.

Authors:  S I Demers; D Phaneuf; R M Tanguay
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

10.  MicroRNA profiling in lymphocytes and serum of tyrosinemia type-I patients.

Authors:  Omer Faruk Karatas; Esra Guzel; Ender Karaca; Serhat Sevli; Erdogan Soyucen; Adnan Yuksel; Mustafa Ozen
Journal:  Mol Biol Rep       Date:  2013-05-07       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.